Key facts
- BiPER Therapeutics’s last known valuation is $5.7M (Feb 2023).
- It has raised $2.9M; the latest was Early Stage VC ($1.2M) in Dec 2025.
- Notable investors include Bpifrance, Region Grand Est, MEDIN Fund Management, Matwin, Quest for Health — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for BiPER Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for BiPER Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BiPER Therapeutics
Operator of a biotechnology company intended to develop first-in-class therapeutics for cancer. The company develops small molecules targeting BiP to induce unresolved endoplasmic reticulum stress, enabling patients to receive therapies that trigger selective death of cancer cells.
- Sector
- Healthcare
- HQ
- Strasbourg, France
- Founded
- 2021
- Employees
- 10
- Website
- biper-tx.com/
- Ownership
- Privately Held (backing)
BiPER Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BiPER Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BiPER Therapeutics in its N-PORT filings yet. We sweep new filings monthly.